Stay updated on BI 695500 vs Rituxan in Low Tumor Burden Follicular Lymphoma Clinical Trial
Sign up to get notified when there's something new on the BI 695500 vs Rituxan in Low Tumor Burden Follicular Lymphoma Clinical Trial page.

Latest updates to the BI 695500 vs Rituxan in Low Tumor Burden Follicular Lymphoma Clinical Trial page
- Check7 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check14 days agoNo Change Detected
- Check22 days agoChange DetectedThe page has removed detailed descriptions of a Phase III clinical trial for BI 695500 versus rituximab, including patient eligibility criteria and treatment protocols, while adding references to lymphoma and an EudraCT number.SummaryDifference31%
- Check29 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check36 days agoNo Change Detected
- Check72 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check87 days agoChange DetectedThe webpage now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with a contact email for assistance.SummaryDifference2%
- Check94 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.1%
Stay in the know with updates to BI 695500 vs Rituxan in Low Tumor Burden Follicular Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the BI 695500 vs Rituxan in Low Tumor Burden Follicular Lymphoma Clinical Trial page.